Compare LSTA & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSTA | CLGN |
|---|---|---|
| Founded | 1980 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4M | 18.4M |
| IPO Year | 2000 | 2015 |
| Metric | LSTA | CLGN |
|---|---|---|
| Price | $5.04 | $0.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $15.00 | $11.00 |
| AVG Volume (30 Days) | 52.6K | ★ 99.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.98 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,283,868.00 | N/A |
| Revenue This Year | N/A | $1,596.12 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 56.90 | N/A |
| 52 Week Low | $1.81 | $0.50 |
| 52 Week High | $4.89 | $4.98 |
| Indicator | LSTA | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 72.59 | 34.59 |
| Support Level | $2.31 | $0.50 |
| Resistance Level | N/A | $1.60 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 98.53 | 63.40 |
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.